Increasing Access to Buprenorphine and Methadone During COVID-19
This dataset, published on PDAPS.org, is cross-sectional and displays key features of state laws increasing access to buprenorphine and methadone during COVID-19 across all 50 states and the District of Columbia approved as of June 1, 2021.
COVID-19 State Medicaid Waivers for Substance Use Disorder Treatment
This dataset is cross-sectional and displays key features of state Medicaid Waivers addressing COVID-19 across all 50 states and the District of Columbia approved as of July 1, 2021.
Naloxone Overdose Prevention Laws
Unintentional drug overdose is a leading cause of preventable death in the United States. Administering naloxone hydrochloride (“naloxone”) can reverse an opioid overdose and prevent unintentional death. Since 2001, states have enacted naloxone laws to increase access, simplify prescribing and dispensing by health care providers, and encourage its use by individuals in a position to assist a person experiencing a drug overdose.
Syringe Service Programs Laws
Across the country, a rise in the misuse of injectable opioids and heroin means more people are at higher risk of contracting infectious diseases from using contaminated syringes. Sharing syringes provides a direct route of transmission for blood-borne diseases such as the hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). Symptoms may not appear for years, meaning individuals who inject drugs may share needles and unknowingly spread diseases to others.